Hendrika M. Oosterkamp

Hendrika M. Oosterkamp

Auto-generated profile, based on publicly available information

Hendrika M. Oosterkamp

Department of Medical Oncology, Haaglanden Medical Center, The Hague, the Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
AGAnne F. de Groot
Anne F. de Groot
DCDanielle Cohen
Danielle Cohen
JHJoan B. Heijns
Joan B. Heijns
CMCaroline M.P.W. Mandigers
Caroline M.P.W. Mandigers
AWAgnes Josephine van de Wouw
Agnes Josephine van de Wouw
Judith KroepJudith Kroep
Judith Kroep
Purpose: In hormone receptor–positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLBC trial studied whether neoadjuvant ribociclib plus letrozole (RL) results in a doubling of complete cell-cycle arrest (CCCA; Ki67 <1% on IHC) compared with CT in the surgical specimen in luminal breast cancer. Patients and Methods: This randomized phase II trial tailored neoadjuvant therapy in postmenopausal patients with early, luminal, HER2-negative, stage II/III breast cancer based on the percentage of Ki67-positive cancer cells after 2 weeks of letrozole. Patients with a Ki67 ≥1% were randomized between RL and standard CT. Secondary endpoints included pathologic response and toxicity. Results: Of 161 registered patients, 70 were randomized, and 66 started the allocated treatment. The CCCA in the surgical specimen was similar for both groups: 35.3% in the RL group and 31.3% in the CT group (P = 0.73). The response according to Miller and Payne was not significantly different between the two groups, nor was the pathologic complete response rate. Overall toxicity was observed more often in the CT group. In the RL group, eight patients discontinued treatment due to toxicity, and in the CT group, 10 patients discontinued treatment. Conclusions: Although the primary endpoint was not met, the NEOLBC trial (NCT03283384) showed a similar CCCA and pathologic response for RL and CT with less toxicity. Therefore, RL as an alternative to neoadjuvant CT merits further investigation.

15 July 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JHJuliane Hannemann
Juliane Hannemann
HOH. M. Oosterkamp
H. M. Oosterkamp
CBC. A. J. Bosch
C. A. J. Bosch
CLC. Loo
C. Loo
AWA. Witteveen
A. Witteveen
MVM. Van de Vijver
M. Van de Vijver
502 Introduction: It is currently not possible to predict sensitivity of locally advanced breast cancer (LABC) to specific drugs. This study was designed to identify gene expression patterns in LABC that can predict response to neoadjuvant therapy with Adriamycine (60 mg/m2) and Cyclophosphamide (600 mg/m2) (AC); or Adriamycine (50 mg/m2) and Docetaxel (75 mg/m2) (AD). Methods: We started a phase III trial for patients with locally advanced breast cancer, randomizing between 6 courses of AC or 6 courses AD. Total RNA was isolated from a 14 G core needle biopsy obtained before treatment. All patients underwent surgery after completing chemotherapy. RNA was isolated from any remaining tumor. Amplified mRNA was hybridized on human 18k cDNA microarrays (NKI microarray facility). Supervised and unsupervised classifications were used to analyze differences between gene expression before and after treatment and to correlate expression profiles with response to the chemotherapy. Results: 62 patients with LABC have been randomized in the study. Good quality RNA from tissue with more than 50% tumor cells was obtained from 46 biopsies and from 18 tumors after chemotherapy. Data from 49 patients were included in the analysis: 25 from the AC arm, 24 from the AD arm. Using two-dimensional unsupervised hierarchical clustering, the tumor and biopsy clustered together in almost all cases when no response to chemotherapy was observed. When partial or complete remission was observed, the untreated biopsy specimens and the tumors after treatment clustered together more closely than the specimen obtained from individual patients before and after treatment. Using 9-fold cross-validation on the whole dataset containing 46 biopsies before and 18 specimen after treatment, an optimal number of 30 genes could be identified to distinguish between specimen before and after treatment with an average performance of 91%. Discussion: When breast carcinomas do not respond to neoadjuvant chemotherapy, there are no large alterations in the gene expression pattern. When tumors respond, a gene expression pattern of 30 genes distinguishes tumors before and after therapy. No significant financial relationships to disclose.

1 September 2014 in Neuro-Oncology
Verified
Journal Article
Open access
WTWalter Taal
Walter Taal
HOH. M. Oosterkamp
H. M. Oosterkamp
AWAnnemiek Walenkamp
Annemiek Walenkamp
HDHendrikus Jan Dubbink
Hendrikus Jan Dubbink
LBL. V. Beerepoot
L. V. Beerepoot
MBMartin J. Van Den Bent
Martin J. Van Den Bent
INTRODUCTION: Treatment options for recurrent glioblastoma remain limited, with only modest activity of second line chemotherapy. Despite the absence of well controlled trials, bevacizumab is widely used for recurrent glioblastoma. Nonetheless, it remains unclear if the high response rates observed after treatment with bevacizumab translate into an overall survival (OS) benefit. We report the first randomized phase II trial on bevacizumab in recurrent glioblastoma with a control arm without bevacizumab. METHODS: This was multicenter phase II study conducted in 14 Dutch sites. Patients with a first recurrence of a glioblastoma after chemo-irradiation with temozolomide were randomized between treatment with oral lomustine 110 mg/m2 once every 6 weeks, with bevacizumab 10 mg/kg once every 2 weeks intravenously or with the combination lomustine 110 mg/m2 every 6 weeks and bevacizumab 10 mg/kg every 2 weeks. Response was assessed using the RANO criteria. Primary endpoint was OS at 9 months. A safety analysis was planned after the first ten patients completed two cycles of 6 weeks in the combination arm. RESULTS: 153 patients were randomized, of which 148 were eligible. After the safety analysis the lomustine dosage in the combination arm was reduced to 90 mg/m2 because of thrombocytopenia, resulting in bevacizumab dose delays. After reduction the treatment in the combination arm was well tolerated. The percentage 9 month OS (95% confidence interval) was 43% (29, 57) in the lomustine arm, 38% (25, 51) in the bevacizumab arm, and 59% (43, 72) in the bevacizumab/lomustine 90 arm. Response rates were 35-40% for bevacizumab treated patients, and 5% in the lomustine single agent arm. CONCLUSION: This study does not show a meaningful OS at 9 months after treatment with bevacizumab alone. However, the results of combination therapy of bevacizumab with lomustine met the prespecified criterion for further phase III studies. AKNOWLEDGMENTS: This study was supported by an unrestricted grant from Roche Nederland bv. The study was also supported by grant nr DDHK 2010-4678 from the ‘KWF Kankerbestrijding’ (Dutch Cancer Society).

1 August 2025
Verified
Other
Open access
AGAnne F. de Groot
Anne F. de Groot
DCDanielle Cohen
Danielle Cohen
JHJoan B. Heijns
Joan B. Heijns
CMCaroline M.P.W. Mandigers
Caroline M.P.W. Mandigers
AWAgnes Josephine van de Wouw
Agnes Josephine van de Wouw
Judith KroepJudith Kroep
Judith Kroep
Supplementary Table S3. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.

1 August 2025
Verified
Other
Open access
AGAnne F. de Groot
Anne F. de Groot
DCDanielle Cohen
Danielle Cohen
JHJoan B. Heijns
Joan B. Heijns
CMCaroline M.P.W. Mandigers
Caroline M.P.W. Mandigers
AWAgnes Josephine van de Wouw
Agnes Josephine van de Wouw
Judith KroepJudith Kroep
Judith Kroep
Supplementary Table S2. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.

1 August 2025
Verified
Other
Open access
AGAnne F. de Groot
Anne F. de Groot
DCDanielle Cohen
Danielle Cohen
JHJoan B. Heijns
Joan B. Heijns
CMCaroline M.P.W. Mandigers
Caroline M.P.W. Mandigers
AWAgnes Josephine van de Wouw
Agnes Josephine van de Wouw
Judith KroepJudith Kroep
Judith Kroep
Supplementary Table S1. Representativeness of study participants.